Anticancer Research is an international print and online monthly journal designed to rapidly publish peer-reviewed original works and reviews on all aspects of experimental and clinical cancer research.
Impact factor (2021): 2.435Current issue contents >>
In Vivo is an international online and open-access journal designed to bring together peer-reviewed original works and reviews on experimental and clinical biomedical research within the frames of human physiology, pathology and disease management.
Impact factor (2021): 2.406Current issue contents >>
Cancer Genomics & Proteomics
Cancer Genomics & Proteomics is an international peer-reviewed online and open-access journal designed to rapidly publish high quality articles and reviews on the application of genomic and proteomic technology to experimental and clinical cancer research.
Impact factor (2021): 3.395Current issue contents >>
Cancer Diagnosis & Prognosis
Cancer Diagnosis & Prognosis is an international online open-access peer-reviewed journal, designed to rapidly publish original and review papers on experimental and clinical research advancing the knowledge on the diagnosis and prognosis of all types of cancer, leukemia and metastasis.
Call for papers
Special Issue of Anticancer Research on NEW ANTICANCER AGENTS 2024
TOPICS: A. Experimental studies on “New Anticancer Agents”
- Synthesis and evaluation in vitro and in vivo
- Mechanism of action
- Reversal of resistance to anticancer agents
- Oncolytic viruses
B. Clinical studies on “New Anticancer Agents”
- Clinical trials
- Combination chemotherapy
- Immunotherapeutic agents
- New methodologies in drug delivery
Publication date: March 1, 2024
Submission deadline: December 31, 2023
Instructions for the preparation and submission of reviews and original articles: www.iiar-anticancer.org
Anticancer Research, In Vivo, Cancer Genomics & Proteomics, and Cancer Diagnosis & Prognosis are independent international journals, published by the International Institute of Anticancer Research (IIAR), and have had no relation or association with other publishers since their establishment.
At the IIAR, we are committed to maintaining the highest content quality and the most rapid processing of submitted articles to our four journals.
All submitted articles are peer-reviewed to secure a valid assessment. Our preliminary review includes a detailed assessment of the suitability and validity of the conclusions of all cited references.
We value the support of our policy by our Authors and Readers and we look forward to receiving comments and suggestions for the
continuous improvement of our services.
Now you can access the entire contents of the IIAR journals published from 2013 till today
with ease on your Android© or iOS phone or tablet with our newly designed app, freely available on Google Play Store and App Store
Articles in ANTICANCER RESEARCH are fully available to everyone as open access 2 years after publication.
IN VIVO (from January 2017) and CANCER GENOMICS & PROTEOMICS (from January 2013) are published online-only with open access.
CANCER DIAGNOSIS & PROGNOSIS (from March 2021) is published online-only with open access.
Should you come across any errors in this website, please inform: firstname.lastname@example.org